Ovarian cancer related to molar pregnancy. Systematic review [ Cáncer ovárico relacionado a embarazo molar. Revisión sistemática]
DOI:
https://doi.org/10.62574/wyxrmf95Keywords:
ovary, genitalia female, diagnostic imagingAbstract
Objective: to analyse ovarian cancer related to molar pregnancy. Method: Systematic review. Results and conclusion: The evidence analysed in this systematic review establishes a significant association between molar pregnancy and the subsequent development of ovarian cancer, with a relative risk of 1.32 according to cohort studies. The most relevant pathogenic mechanisms include shared genetic alterations in tumour suppressor genes, proliferative effects of prolonged exposure to hCG on ovarian tissue, immunological dysregulation and the carcinogenic potential of chemotherapeutic agents used in the treatment of GTN.
Downloads
References
Smith HO, Qualls CR, Prairie BA, Padilla LA, Rayburn WF. Gestational trophoblastic disease diagnosed as ovarian carcinoma: A case-control study. Gynecol Oncol. 2022;86(2):177-181. doi:10.1006/gyno.2002.6685.
Seckl MJ, Sebire NJ, Fisher RA, Golfier F, Massuger L, Sessa C. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;24 Suppl 6. doi:10.1093/annonc/mdt343.
Yang J, Li C, Li Y, et al. The long-term risk of female malignancies among women with a hydatidiform mole or gestational trophoblastic neoplasia: a historical cohort study in China. J Cancer Res Clin Oncol. 2020;146(4):991-998.
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2019;203(5):531-539.
Ghorbani F, Ebrahimi E, Khatami F, Mirzaei A. Diagnosis and management of gestational trophoblastic neoplasia: A review. J Obstet Gynaecol Res. 2022;48(8):1783-1792.
Shih I-M, Kurman RJ. Pathogenesis of low-grade and high-grade ovarian serous carcinoma. Int J Gynecol Pathol. 2021;40(1):8-17.
Louie KS, Parsons HM, Castro F, et al. Risk factors for gestational trophoblastic neoplasia: A population-based study. Obstet Gynecol. 2021;137(6):1054-1061.
Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. Ann Oncol. 2020;31(2):290-296.
Fang C, Huang R, Wei L, et al. Clinical characteristics and prognosis of patients with gestational trophoblastic neoplasia: A retrospective cohort study. BMC Cancer. 2022;22(1):567.
Schmid P, Nagai Y, Agarwal R, et al. Treatment of gestational trophoblastic neoplasia with EMA/CO: results of a large retrospective analysis and the future role of genetic analysis. J Clin Oncol. 2021;39(24):2655-2663.
Lurain JR, Goldstein DP. Modern management of gestational trophoblastic disease. Hematol Oncol Clin North Am. 2020;34(1):181-197.
González Martín A, Redondo A, De Santiago J, Díaz-Padilla I. Guía SEOM de diagnóstico y tratamiento del cáncer de ovario. Clin Transl Oncol. 2020;22(8):1096-1106.
Álvarez Secord A, Monk BJ. Tratamiento actual del cáncer epitelial de ovario. Rev Colomb Obstet Ginecol. 2019;70(2):120-131.
Santaballa A, Matías-Guiu X, Redondo A, Colás E, García Álvarez A, Gil-Moreno A. Cáncer de ovario y trompas de Falopio. Progresos en Obstet Ginecol. 2021;64(1):42-58.
Kiser D, Elhanan G, Bolze A, et al. Screening Familial Risk for Hereditary Breast and Ovarian Cancer. JAMA Netw Open. 2024;7(9):e2435901. Published 2024 Sep 3. doi:10.1001/jamanetworkopen.2024.35901
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Denebb Arlett Carrera-Calle , Carlos Eduardo Gordón-Llerena, Bladimir de Jesús Lozano-León, Barbara Alejandra Núñez-Yánez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
